Enlightened therapy of the disorders of cornification

Clinics in Dermatology

Volumn 21, Issue 4, 2003, Pages 269-273

  Williams, Mary L ^a   Elias, Peter M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYACID; ANTIINFECTIVE AGENT; CERAMIDE; CHOLESTEROL DERIVATIVE; GLYCEROL; HUMECTANT; IMMUNOSUPPRESSIVE AGENT; KERATOLYTIC AGENT; LANOLIN; PETROLATUM; RETINOID; SERINE PROTEINASE INHIBITOR; STEROID; TACROLIMUS; UREA;

CONGENITAL ICTHYOSIFORM ERYTHRODERMA; DISEASE COURSE; EPIDERMAL HYPERKERATOSIS; HARLEQUIN ICHTHYOSIS; HUMAN; ICHTHYOSIS; ICHTHYOSIS VULGARIS; KERATODERMA; LAMELLAR ICHTHYOSIS; NETHERTON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; SKIN FUNCTION; STRATUM CORNEUM; TOXICITY;

EID: 0142156000     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(03)00059-2     Document Type: Article

References (15)

1. Fleckman P., Holbrook K.A., Dale B.A., Sybert V.P. Keratinocytes cultured from subjects with ichthyosis vulgaris are phenotypically abnormal. J Invest Dermatol. 88:1987;640-645.
2. Scott I.R., Richards S., Harding C., et al. Does catabolism of stratum corneum proteins yield functionally active molecules? Ann N Y Acad Sci. 548:1988;125-136.
3. Sato J, Nakanishi J, Denda M, . Cholesterol sulfate inhibits proteases which are in volved in desquamation of stratum corneum. J Invest Dermatol 1998;111:189-93.
4. Ohman H., Vahlquist A. The pH gradient over the stratum corneum differs in X-linked recessive and autosomal dominant ichthyosis: a clue to the molecular origin of the "acid skin mantle"? J Invest Dermatol. 111:1998;674-677.
5. Fartasch M., Teal J., Menon G.K. Mode of action of glycolic acid on human stratum corneum: ultrastructural and functional evaluation of the epidermal barrier. Arch Dermatol Res. 289:1997;404-409.
6. Zettersten E., Man M.Q., Sato J., et al. Recessive x-linked ichthyosis: role of cholesterol-sulfate accumulation in the barrier abnormality. J Invest Dermatol. 111:1998;784-790.
7. Russel L.J., DiGiovanna J.J., Rogers G.R., et al. Mutations in the greater transquataminase 1 in autosomal recessive ichthyosis. Nat Genet. 5:1995;276-283.
8. Jobard F., Lefevre C., Karaduman A., et al. Lipoxygenase-3 (ALOXE3) and 12(R)-lipoxygenase (ALOX12B) are mutated in non-bullous congenital ichthyosiform erythroderma (NCIE) linked to chromosome 17p13.1. Hum Mol Genet. 11:2002;107-113.
9. Milner M.E., O'Guin W.M., Holbrook K.A., Dale P.A. Abnormal lamellar granules in harlequin ichthyosis. J Invest Dermatol. 99:1992;824-829.
10. Williams M.L., Elias P.M. Nature of skin fragility in patients receiving retinoids for systemic effect. Arch Dermatol. 117:1981;611-619.
11. Cheng J., Syder A.J., Yu Q.C., et al. The genetic basis of epidermolytic hyperkeratosis: a disorder of differentiation-specific epidermal keratin genes. Cell. 70:1992;811-819.
12. Kremer H., Zeeuwen P., McLean W.H., et al. Ichthyosis bullosa of Siemens is caused by mutations in the keratin 2e gene. J Invest Dermatol. 103:1994;286-289.
13. Schmuth M., Yosipovitch G., Williams M.L., et al. Pathogenesis of the permeability barrier abnormality in epidermolytic hyperkeratosis. J Invest Dermatol. 117:2001;837-847.
14. Chavanas S., Bodemer C., Rochat A., et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet. 25:2000;141-142.
15. Allen A., Siegfried E., Silverman R., et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol. 137:2001;747-750.